SCYNEXIS (NASDAQ:SCYX) & Clene (NASDAQ:CLNN) Head to Head Contrast

Clene (NASDAQ:CLNN) and SCYNEXIS (NASDAQ:SCYX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.

Valuation & Earnings

This table compares Clene and SCYNEXIS”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$200,000.00	249.41	-$26.17 million	($3.50)	-1.10
SCYNEXIS	$20.60 million	1.84	-$8.61 million	($2.09)	-1.82

SCYNEXIS has higher revenue and earnings than Clene. SCYNEXIS is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Clene and SCYNEXIS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Clene	-20,063.96%	N/A	-137.04%
SCYNEXIS	N/A	-44.15%	-32.61%

Risk & Volatility

Clene has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Clene and SCYNEXIS, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1	0	6	0	2.71
SCYNEXIS	1	0	2	0	2.33

Clene currently has a consensus target price of $34.00, suggesting a potential upside of 785.42%. SCYNEXIS has a consensus target price of $33.00, suggesting a potential upside of 766.14%. Given Clene’s stronger consensus rating and higher probable upside, analysts plainly believe Clene is more favorable than SCYNEXIS.

Insider and Institutional Ownership

23.3% of Clene shares are held by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are held by institutional investors. 28.3% of Clene shares are held by company insiders. Comparatively, 4.1% of SCYNEXIS shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

About Clene

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

About SCYNEXIS

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.